Teriparatide
- Generic Name
- Teriparatide
- Brand Names
- Forsteo, Forteo, Movymia, Kauliv, Sondelbay, Teriparatide Sun, Terrosa, Livogiva
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 52232-67-4
- Unique Ingredient Identifier
- 10T9CSU89I
- Background
Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic th...
- Indication
Teriparatide is indicated:
- Associated Conditions
- Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Primary Osteoporosis
- Associated Therapies
- -
TEVA Stock Down 10% in a Month: Should You Buy the Dip?
Teva Pharmaceutical Industries Limited's TEVA stock declined 10% despite strong Q3 results, driven by underwhelming guidance. The company's branded drugs Austedo and Ajovy are key growth drivers, with expected sales of $1.6 billion and $500 million in 2024, respectively. Teva's generics and biosimilars pipeline is robust, with several launches expected by 2027. The company resolved opioid litigation for $4.25 billion, and its stock valuation is attractive, making it a potential buying opportunity for long-term investors.
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin
Entera Bio and OPKO Health report positive PK/PD results for their oral oxyntomodulin tablet, showing significant systemic exposure and glucose reduction in animal models, supporting further development for obesity and metabolic disorders.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath